---
firstreceived_date: August 3, 2015
is_fda_regulated: 'No'
reference: []
overall_contact_backup: {}
completion_date:
  attributes:
    type: Actual
  value: October 2012
responsible_party: {}
firstreceived_results_date: 
is_section_801: 
detailed_description:
  textblock: |-
    This is an investigator-initiated, open-label, single-center, proof-of-concept-study. The
          study medication consists of L-arginine and metformin. The duration of the study is 16 weeks
          and comprehends one screening and four study visits.
link: []
has_expanded_access: 'No'
id: NCT02516085
intervention:
- intervention_name: Metformin
  other_name: []
  description: 
  arm_group_label:
  - L-arginine and metformin
  intervention_type: Drug
- intervention_name: L-Arginine
  other_name: []
  description: 
  arm_group_label:
  - L-arginine and metformin
  intervention_type: Drug
source: University Hospital, Basel, Switzerland
eligibility:
  gender: Both
  maximum_age: 10 Years
  sampling_method: 
  minimum_age: 7 Years
  study_pop: {}
  criteria:
    textblock: |-
      Inclusion Criteria:

                -  Molecular diagnosis of DMD

                -  Patients 7 - 10 years of age at time of screening

                -  Ambulant

              Exclusion Criteria:

                -  Previous (3 months or less) or concomitant participation in another therapeutic trial

                -  Use of L-arginine, L-citrulline or metformin within the last 3 months

                -  Known individual hypersensitivity to L-citrulline or metformin

                -  Other chronic disease or clinical relevant limitation of renal, liver, heart function
                   according to discretion of the investigator
  healthy_volunteers: 'No'
removed_countries: {}
other_outcome: []
primary_completion_date:
  attributes:
    type: Actual
  value: October 2012
last_injected: '2015-08-07T22:35:30.143Z'
intervention_browse:
  mesh_term:
  - Metformin
target_duration: 
number_of_arms: '1'
start_date: January 2012
why_stopped: 
id_info:
  org_study_id: DMD01
  secondary_id: []
  nct_alias: []
  nct_id: NCT02516085
acronym: 
arm_group:
- description: 7.5 g L-arginine p.o. and 500 mg metformin p.o. per day (3x 2.5 g,
    respectively 3x 250 mg) for 16 weeks
  arm_group_label: L-arginine and metformin
  arm_group_type: Experimental
sponsors:
  collaborator: []
  lead_sponsor:
    agency: University Hospital, Basel, Switzerland
    agency_class: Other
secondary_outcome:
- safety_issue: 'No'
  time_frame: baseline to week 16
  description: indirect calorimetry, Dual-Energy X-Ray Absorptiometry, quantitative
    thigh muscle MRI, clinical score of muscle performance
  measure: In vivo change of muscle metabolism
study_type: Interventional
biospec_retention: 
overall_status: Completed
primary_outcome:
- safety_issue: 'No'
  time_frame: baseline to week 16
  description: mitochondrial protein expression analysis in muscular biopsies
  measure: Mean change of muscle metabolism
overall_official:
- first_name: 
  last_name: Dirk Fischer, MD
  middle_name: 
  affiliation: University of Basel, Children's Hospital
  degrees: 
  role: Principal Investigator
phase: Phase 1
location_countries: {}
condition:
- Duchenne Muscular Dystrophy
clinical_results: {}
study_design: 'Endpoint Classification: Safety/Efficacy Study, Intervention Model:
  Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment'
keyword: []
results_reference: []
oversight_info:
  has_dmc: 'Yes'
  authority:
  - 'Switzerland: Swissmedic'
number_of_groups: 
location: []
official_title: 
verification_date: August 2015
required_header:
  url: https://clinicaltrials.gov/show/NCT02516085
  link_text: Link to the current ClinicalTrials.gov record.
overall_contact: {}
brief_title: Improved Muscle Function in Duchenne Muscular Dystrophy Through L-Arginine
  and Metformin
biospec_descr: {}
condition_browse:
  mesh_term:
  - Muscular Dystrophies
  - Muscular Dystrophy, Duchenne
brief_summary:
  textblock: |-
    The purpose of the study is to show that the intake of L-arginine and metformin improves
          muscle function and delays disease progression in patients with Duchenne's muscular
          dystrophy.
enrollment:
  attributes:
    type: Actual
  value: '5'
lastchanged_date: August 5, 2015
